
1. Microbiol Spectr. 2021 Oct 31;9(2):e0113821. doi: 10.1128/Spectrum.01138-21. Epub
2021 Oct 20.

COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the 
Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the 
First French Pandemic Wave.

Bretagne S(1)(2)(3), Sitbon K(1), Botterel F(4), Dellière S(1)(2)(3),
Letscher-Bru V(5), Chouaki T(6), Bellanger AP(7), Bonnal C(8), Fekkar A(9),
Persat F(10), Costa D(11), Bourgeois N(12), Dalle F(13), Lussac-Sorton F(14),
Paugam A(3)(15), Cassaing S(16), Hasseine L(17), Huguenin A(18), Guennouni N(19),
Mazars E(20), Le Gal S(21), Sasso M(22), Brun S(23), Cadot L(24), Cassagne C(25),
Cateau E(26), Gangneux JP(27), Moniot M(28), Roux AL(29), Tournus C(30),
Desbois-Nogard N(31), Le Coustumier A(32), Moquet O(33), Alanio A(1)(2)(3),
Dromer F(1); French Mycoses Study Group.

Author information: 
(1)Institut Pasteur, Université de Paris, CNRS UMR2000, unité de Mycologie
Moléculaire, Centre national de Référence Mycoses Invasives et Antifongiques,
Paris, France.
(2)Laboratoire de Parasitologie-Mycologie, Hôpital Saint Louis, Assistance
Publique-Hôpitaux De Paris (AP-HP), Paris, France.
(3)Université de Paris, Paris, France.
(4)Assistance Publique-Hôpitaux De Paris (AP-HP), Hôpital Henri Mondor,
Université Paris-Est Créteil Val-de-Marne, Créteil, France.
(5)Service de Parasitologie et de Mycologie Médicale, CHU de Strasbourg,
Strasbourg, France.
(6)Laboratoire de Parasitologie-Mycologie, CHU Amiens-Picardie, Amiens, France.
(7)Laboratoire de Parasitologie-Mycologie, CHU Besançon, Besançon, France.
(8)Assistance Publique-Hôpitaux De Paris (AP-HP), Laboratoire de
Parasitologie-Mycologie, Hôpital Universitaire Bichat, Paris, France.
(9)Assistance Publique-Hôpitaux De Paris (AP-HP), Groupe Hospitalier La
Pitié-Salpêtrière, Service de Parasitologie Mycologie, Sorbonne Université,
Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Paris,
France.
(10)Hospices Civils de Lyongrid.413852.9, Service de Parasitologie et Mycologie
Médicale, Hôpital de la Croix-Rousse, Lyon-Université Claude Bernard Lyon 1,
Lyon, France.
(11)Laboratoire de Parasitologie-Mycologie, CHU Charles-Nicolle, Rouen, France.
(12)Laboratoire de Parasitologie-Mycologie, CHU de Montpellier, Montpellier,
France.
(13)Laboratoire de Parasitologie Mycologie, Centre Hospitalier Universitaire de
Dijon-Hôpital François Mitterrand, Dijon, France.
(14)Department of Parasitology, Bordeaux University Hospital, Bordeaux, France.
(15)Assistance Publique-Hôpitaux De Paris (AP-HP), Hôpital Cochin, Paris, France.
(16)Service de Parasitologie-Mycologie, Hôpital Purpan Toulouse, CHU Toulouse,
Toulouse, France.
(17)Laboratoire de Parasitologie Mycologie CHU de Nice, Nice, France.
(18)Parasitologie Mycologie-Laboratoire de Parasitologie-Mycologie, Pôle de
Biopathologie, CHU de Reims, Université de Reims Champagne Ardenne, Reims,
France.
(19)Assistance Publique-Hôpitaux De Paris (AP-HP), Service de Bactériologie,
Virologie, Parasitologie et Hygiène, Hôpital Necker-Enfants Malades, IHU Imagine,
Paris, France.
(20)CH de Valenciennes, Laboratoire de Microbiologie, Valenciennes, France.
(21)Laboratoire de Parasitologie et Mycologie, Hôpital de La Cavale Blanche, CHU 
de Brest, Brest, France.
(22)Laboratoire de Parasitologie Mycologie CHU Nîmes, Nîmes, France.
(23)Assistance Publique-Hôpitaux De Paris (AP-HP), Laboratoire de Parasitologie
Mycologie Hôpital Avicenne, Bobigny, France.
(24)Département d'Hygiène Hospitalière, CHU Montpellier, Montpellier, France.
(25)IHU Marseille-Institut Hospitalier Universitaire Méditerranée Infection,
Marseille, France.
(26)Laboratoire de Parasitologie-Mycologie, CHU de Poitiers, Poitiers, France.
(27)CHU de Rennes, Université de Rennes, Institut de Recherche en Santé,
Environnement et Travail (IRSET), Rennes, France.
(28)Laboratoire de Parasitologie-Mycologie, CHU Clermont-Ferrand,
Clermont-Ferrand, France.
(29)Assistance Publique-Hôpitaux De Paris (AP-HP), Hôpital Raymond Poincaré
Garches, Hôpital Ambroise Paré, Boulogne Billancourt, France.
(30)Laboratoire de Microbiologie, Centre Hospitalier de Saint-Denis, Saint-Denis,
France.
(31)Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de
Martiniquegrid.412874.c, Fort-de-France, La Martinique, France.
(32)Centre Hospitalier Intercommunal de Bigorre, Tarbes, France.
(33)Laboratoire de Parasitologie-Mycologie, Centre Hospitalier de Beauvais,
Beauvais, France.

The aim of this study was to evaluate diagnostic means, host factors, delay of
occurrence, and outcome of patients with COVID-19 pneumonia and fungal
coinfections in the intensive care unit (ICU). From 1 February to 31 May 2020, we
anonymously recorded COVID-19-associated pulmonary aspergillosis (CAPA), fungemia
(CA-fungemia), and pneumocystosis (CA-PCP) from 36 centers, including results on 
fungal biomarkers in respiratory specimens and serum. We collected data from 154 
episodes of CAPA, 81 of CA-fungemia, 17 of CA-PCP, and 5 of other mold infections
from 244 patients (male/female [M/F] ratio = 3.5; mean age, 64.7 ± 10.8 years).
CA-PCP occurred first after ICU admission (median, 1 day; interquartile range
[IQR], 0 to 3 days), followed by CAPA (9 days; IQR, 5 to 13 days), and then
CA-fungemia (16 days; IQR, 12 to 23 days) (P < 10-4). For CAPA, the presence of
several mycological criteria was associated with death (P < 10-4). Serum
galactomannan was rarely positive (<20%). The mortality rates were 76.7% (23/30) 
in patients with host factors for invasive fungal disease, 45.2% (14/31) in those
with a preexisting pulmonary condition, and 36.6% (34/93) in the remaining
patients (P = 0.001). Antimold treatment did not alter prognosis (P = 0.370).
Candida albicans was responsible for 59.3% of CA-fungemias, with a global
mortality of 45.7%. For CA-PCP, 58.8% of the episodes occurred in patients with
known host factors of PCP, and the mortality rate was 29.5%. CAPA may be in part 
hospital acquired and could benefit from antifungal prescription at the first
positive biomarker result. CA-fungemia appeared linked to ICU stay without
COVID-19 specificity, while CA-PCP may not really be a concern in the ICU.
Improved diagnostic strategy for fungal markers in ICU patients with COVID-19
should support these hypotheses. IMPORTANCE To diagnose fungal coinfections in
patients with COVID-19 in the intensive care unit, it is necessary to implement
the correct treatment and to prevent them if possible. For COVID-19-associated
pulmonary aspergillosis (CAPA), respiratory specimens remain the best approach
since serum biomarkers are rarely positive. Timing of occurrence suggests that
CAPA could be hospital acquired. The associated mortality varies from 36.6% to
76.7% when no host factors or host factors of invasive fungal diseases are
present, respectively. Fungemias occurred after 2 weeks in ICUs and are
associated with a mortality rate of 45.7%. Candida albicans is the first yeast
species recovered, with no specificity linked to COVID-19. Pneumocystosis was
mainly found in patients with known immunodepression. The diagnosis occurred at
the entry in ICUs and not afterwards, suggesting that if Pneumocystis jirovecii
plays a role, it is upstream of the hospitalization in the ICU.

DOI: 10.1128/Spectrum.01138-21 
PMCID: PMC8528108
PMID: 34668768  [Indexed for MEDLINE]

